New York is currently home to 4483 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol
Recruiting
Ovarian reserve defines the quantity and quality of the ovarian primordial follicular pool. Diminished ovarian reserve (DOR) indicates a reduction in the quantity of ovarian follicular pool to less than expected for age. It is an important cause of infertility in many couples. To date, there is no clear consensus in the literature on the definition of diminished ovarian reserve, and it is unclear whether low oocyte yield results from an abnormal atresia rate of the follicle pool, or from a lowe... Read More
Gender:
FEMALE
Ages:
Between 20 years and 45 years
Trial Updated:
10/13/2023
Locations: Northwell Fertility, Manhasset, New York
Conditions: Infertility, Diminished Ovarian Reserve, IVF
Point of Care Ultrasound to Predict Intensive Care Unit Admission of Patients Presenting With Sepsis to the Emergency Department
Recruiting
The FloPatch device will be applied to 150 septic patients in the emergency department before they receive fluid resuscitation. This study will assess whether initial FloPatch measured volume-responsiveness and volume of fluids used will predict a composite outcome of mortality, intensive care unit admission, or rapid response team activation. The development of fluid unresponsiveness throughout the initial fluid resuscitation will be assessed and its association with the composite outcome will... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/12/2023
Locations: North Shore University Hospital, Manhasset, New York
Conditions: Sepsis
Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US
Recruiting
This is a multi-center, cross-sectional, and prospective study that will recruit patients from multiple hospitals or outpatient clinics in the USA to the comparison of iLivTouch and FibroScan for the assessment of liver fibrosis and steatosis in adult patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2023
Locations: NYU Langone, New York, New York
Conditions: Liver Fibrosis, Fatty Liver
PRagmatic EVAluation of a Quality Improvement Program for People Living With Modifiable High-risk COPD.
Recruiting
A 3-year cluster randomized controlled trial of the impact of a quality improvement and clinical decision support package versus usual care for patients with modifiable high-risk chronic obstructive pulmonary disease with or without a current diagnosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2023
Locations: Mount Sinai, New York, New York
Conditions: Chronic Obstructive Pulmonary Disease
ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEF
Recruiting
The overall hypothesis is that treatment with the SGLT2 inhibitor Ertugliflozin induces a differential regulation in interstitial fluid vs plasma volume, with more reduction of the volume from the interstitial fluid than from the circulating plasma volume, which results in Ertugliflozin inducing more potent congestion relief with minimal impact on blood volume and organ perfusion. Ertugliflozin reduces the levels of sodium and water from the skin and the interstitial tissue (which improves tissu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2023
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Heart Failure With Reduced Ejection Fraction, Congestion
Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations
Recruiting
This phase II trial studies how well olaparib works in treating patients with biliary tract cancer that has spread to other places in the body (metastatic) and with aberrant DNA repair gene mutations. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2023
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Bile Duct Adenocarcinoma, Fanconi Anemia Complementation Group Gene Mutation, Metastatic Bile Duct Carcinoma, PTEN Gene Deletion
SeeMe: An Automated Tool to Detect Early Recovery After Brain Injury
Recruiting
Early prediction of outcomes after acute brain injury (ABI) remains a major unsolved problem. Presently, physicians make predictions using clinical examination, traditional scoring systems, and statistical models. In this study, we will use a novel technique, "SeeMe," to objectively assess the level of consciousness in patients suffering from comas following ABI. SeeMe is a program that quantifies total facial motion over time and compares the response after a spoken command (i.e. "open your eye... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/10/2023
Locations: Stony Brook University Hospital, Stony Brook, New York
Conditions: Disorder of Consciousness, Consciousness, Loss of, Trauma, Brain, Traumatic Brain Injury, Acute Brain Injury
LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC
Recruiting
The study evaluates the efficacy and safety of two strengths of LUT014 Gel topically applied once a day for 4 weeks, compared to placebo, in metastatic colorectal cancer (mCRC) patients who developed Grade 2 or non-infected Grade 3 EGFRI induced acneiform lesions
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/05/2023
Locations: Memorial Sloane Kettering, New York, New York
Conditions: EGFRI Induced Acneiform Lesions
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter, study to evaluate the efficacy, safety, and pharmacokinetics (PK) of budesonide extended-release tablets for the induction of remission in pediatric subjects, with active, mild to moderate ulcerative colitis (UC). Subjects will be permitted to continue taking background oral or rectal 5-aminosalicylate (5-ASA) products.
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
10/05/2023
Locations: Bausch Health Site 006, Bronx, New York
Conditions: Ulcerative Colitis
CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology
Recruiting
This is a prospective, randomized, controlled, multi-center, study in which 150 evaluable subjects will be randomized 1:1 to receive either a Protect CAN-Stim or SNS InterStim® system. Subjects from both groups will immediately start with therapy. The primary endpoint is a ≥ 50% reduction in number of incontinence episodes associated with urgency at the 3-month visit, with additional measurements assessed at 14 days, 1, 6, 9 and 12-months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2023
Locations: Urology - Iris Cantor Men's Health Center, New York, New York
Conditions: Urinary Incontinence, Urge
Triple-masking v Double-masking: a Trial of Scientific Publication in Public Health
Recruiting
The trial is designed to determine whether knowledge of the identity of the authors, their institutions and of the reviewers of a given article submitted to American Journal of Public Health impacts the final editorial decision. The concept of triple masked editorial process (where editors are unaware of author identities and affiliations in addition to the authors' and reviewers' identities being masked from one another) compared to a double masked process (only authors' and reviewers' identiti... Read More
Gender:
ALL
Ages:
All
Trial Updated:
10/02/2023
Locations: QueensC, New York, New York
Conditions: Publication of Articles Submitted to the American Journal of Public Health
Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer
Recruiting
This is a pilot study using \[18F\]F AraG PET imaging to evaluate the immunological response to checkpoint inhibitor therapy (CkIT) in patients with advanced NSCLC tumors at multiple study sites. The main objectives of the study are to quantify the change in \[18F\]F AraG PET signal before and after CkIT therapy, and to correlate this change in \[18F\]F AraG PET signal with a radiographic response.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/27/2023
Locations: Stony Brook University, Stony Brook, New York
Conditions: Non Small Cell Lung Cancer